Studying the effectiveness of various laser therapies in the treatment of acanthosis nigricans

Investigation and comparison of the effectiveness of fractional QS 1064 nm ND:YAG laser and fractional 2940-nm erbium YAG laser and their combination in acanthosis nigricans; A randomized, controlled, blinded, parallel group, clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241205063955N1

Enrollment

Registered

2025-08-17

Start date

2024-12-25

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acanthosis Nigricans. Acanthosis nigricans

Interventions

Intervention 1: One area will be randomly treated with a 106nm Q-switched fractional ND YAG laser. All patients will receive three sessions of treatment with the aforementioned lasers at three-week in

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with skin types 1-4 Patients with simultaneous darkening of the armpit and neck area (including acanthosis nigricans and non-acanthosis nigricans)

Exclusion criteria

Exclusion criteria: Age under 18 years Patients who have received laser treatment within the last three months. Patients with serious underlying disease Patients with a history of underlying disease, including diabetes and autoimmune connective tissue disease, that affect the wound healing process. Patients with active viral infection. History of malignancy or chemotherapy. Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Primary outcome: Acanthosis Nigricans Area and Severity Index. Timepoint: 1) At the beginning of the plan and before starting any treatment. 2) Before the second laser therapy session. 3) Before the third laser therapy session. 4) After the end of the treatment period. Method of measurement: Acanthosis Nigricans Area and Severity Index.	—

Secondary

Measure	Time frame
Patient Satisfaction Scale. Timepoint: 1) At the beginning of the plan and before starting any treatment. 2) Before the second laser therapy session. 3) Before the third laser therapy session. 4) After the end of the treatment period. Method of measurement: Patient Satisfaction Scale.;Physician global assessment score. Timepoint: At the beginning of the plan and before starting any treatment. 2) Before the second laser therapy session. 3) Before the third laser therapy session. 4) After the end of the treatment period. Method of measurement: physician global assessment score.	—

Measure

Time frame

Patient Satisfaction Scale. Timepoint: 1) At the beginning of the plan and before starting any treatment. 2) Before the second laser therapy session. 3) Before the third laser therapy session. 4) After the end of the treatment period. Method of measurement: Patient Satisfaction Scale.;Physician global assessment score. Timepoint: At the beginning of the plan and before starting any treatment. 2) Before the second laser therapy session. 3) Before the third laser therapy session. 4) After the end of the treatment period. Method of measurement: physician global assessment score.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehraneh Karimzadeh

Iran University of Medical Sciences

karimzadeh.mehraneh@gmail.com+98 937 298 8118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026